Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 217, Issue 3, Pages 451-455Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix592
Keywords
Ebola virus; vaccine; immunization; RNA; antibody response
Categories
Funding
- Moderna Therapeutics
- National Institutes of Health [1R01AI102887-01A1]
Ask authors/readers for more resources
Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available